VEGFR1/Flt-1 Antibody [Alexa Fluor™ Plus 488]

• Reactivity: Mu
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor Plus 488

VEGFR1/Flt-1 Antibody [Alexa Fluor™ Plus 488] Summary

• Specificity: Detects mouse VEGFR1/Flt-1 in ELISAs and Western blots.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for VEGFR1/Flt-1 Antibody [Alexa Fluor™ Plus 488]

• EC 2.7.10
• EC 2.7.10.1
• FLT
• FLT1
• Flt-1
• Fms-like tyrosine kinase 1
• fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascularpermeability factor receptor)
• FRT
• Tyrosine-protein kinase FRT
• Tyrosine-protein kinase receptor FLT
• vascular endothelial growth factor receptor 1
• Vascular permeability factor receptor
• VEGF R1
• VEGFR1
• VEGFR-1

Background

VEGFR1 is one of the five receptor tyrosine kinases (RTKs) (VEGFR1, KDR/Flk-1, Flt-4, Tie-1, and Tek/Tie-2) whose expression is almost exclusively restricted to the endothelial cells. Tie-1 and tek/tie-2 define a new class of RTKs containing two immunoglobulin-like domains, three EGF homology domains and three fibronectin type III domains in their extracellular regions. VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, VEGFR3/Flt-4 are members of the class III subfamily of RTKs containing seven immunoglobulin-like repeats in their extracellular domains. All five RTKs are likely to play central roles in vasculogenesis and angiogenesis.

Full length mouse VEGFR1 mRNA encodes a 1333 amino acid (aa) residue precursor with a predicted 22 aa residue signal peptide. Mature VEGFR1 is composed of a 737 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 552 aa residue cytoplasmic domain. As a result of alternative splicing of the mRNA, a cDNA encoding a truncated form of VEGFR1, lacking the seventh immunoglobulin-like domain, the transmembrane and intracellular domains, has been cloned. The recombinant soluble VEGFR1/Fc chimera binds VEGF and PlGF with high affinity and is a potent VEGF antagonist.

1. He, Y. et al. (1999) Molecular Endocrinology 13:537.
2. Ferrara, N. and T. Davis-Smyth (1997) Endocrine Reviews 8:4.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.